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Pquaretic Effect of Lixivaptan, an Oral,
on-Peptide, Selective V2 Receptor Vasopressin
ntagonist, in New York Heart Association
unctional Class II and III Chronic Heart Failure Patients
illiam T. Abraham, MD,* Alireza A. Shamshirsaz, MD,† Kim McFann, MD,† Ron M. Oren, MD,‡
obert W. Schrier, MD†
olumbus, Ohio; Denver, Colorado; and Iowa City, Iowa
OBJECTIVES The purpose of this study was to examine the renal effects of a V2 receptor arginine
vasopressin (AVP) antagonist in heart failure.
BACKGROUND Arginine vasopressin has been implicated in the renal water retention and dilutional
hyponatremia associated with chronic heart failure.
METHODS We examined the effects of the oral, non-peptide, selective V2 receptor antagonist lixivaptan
in 42 diuretic-requiring patients with mild-to-moderate heart failure in a randomized,
double-blind, placebo-controlled, ascending single-dose study. After overnight fluid depri-
vation, patients received single-blind placebo on day 1 (baseline) and double-blind study
medication (placebo [n  12] or lixivaptan 10, 30, 75, 150, 250, or 400 mg [n  5 per dose
group]) on day 1, followed by 4 h of continued fluid restriction and additional 20 h with ad
libitum fluid intake.
RESULTS At all but the 10-mg dose, lixivaptan produced a significant and dose-related increase in urine
volume over 4 h, compared with placebo. During 24 h, increases in urine volume ranged from
1.8 l with placebo to 3.9 l after the 400-mg lixivaptan dose (p  0.01). These increases in
urine volumes were accompanied by significant increases in solute-free water excretion. At
higher doses, serum sodium was significantly increased; AVP antagonism was well tolerated
in these patients.
CONCLUSIONS These observations confirm a role for AVP in the renal water retention associated with heart
failure and suggest that the V2 receptor antagonist lixivaptan may be a promising therapeutic
agent for the treatment of heart failure. (J Am Coll Cardiol 2006;47:1615–21) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.071the American College of Cardiology Foundation
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Tmajor cause of morbidity and mortality in chronic heart
ailure (CHF) relates to the renal sodium and water reten-
ion characteristic of patients with symptomatic disease (1).
urrently available diuretic therapy may initiate or exacer-
ate the dilutional hyponatremia associated with heart
ailure. In this context, it should be noted that hyponatremia
s an indicator of poor prognosis in heart failure patients (2,3).
n agent that can increase solute-free water excretion may thus
acilitate diuresis, prevent or correct hyponatremia, and possi-
ly improve outcome in patients with heart failure.
The role of arginine vasopressin (AVP) in the water
etention and dilutional hyponatremia of heart failure re-
ains controversial. Observations from experimental mod-
ls support a role for AVP in the renal pathophysiology of
eart failure (4–6). Moreover, plasma AVP concentrations
re usually elevated in patients with heart failure and
orrelate, in general, with the clinical and hemodynamic
everity of the disease (7–10), suggesting an important role
or AVP in disease progression. Szatalowicz et al. (7) were
he first to document detectable plasma AVP concentrations
From *The Ohio State University Heart Center, Columbus, Ohio; †University of
olorado, Health Sciences Center, Denver, Colorado; and the ‡University of Iowa
ospitals and Clinics, Iowa City, Iowa. Wyeth-Ayerst Research, Philadelphia,
ennsylvania, supported this study.a
Manuscript received January 11, 2005; revised manuscript received November 20,
005, accepted November 28, 2005.n over 80% of hyponatremic heart failure patients, despite
degree of hypo-osmolality that would normally suppress
VP to undetectable levels in healthy subjects. However,
he ability to fully elucidate the role of AVP in heart failure
nd the potential benefits of antagonizing it has awaited the
evelopment of orally active, non-peptide AVP receptor
ntagonists (11,12). In this regard, renal or V2 receptor
VP antagonists have been shown to reverse water reten-
ion and hyponatremia and to decrease renal medullary
quaporin-2 (AQP-2) in experimental CHF (13,14). The
ffects of such agents in human heart failure have been
ncompletely studied.
Lixivaptan (or VPA-985) (Cardiokine Inc., Philadelphia,
ennsylvania) is a potent, orally active, non-peptide com-
etitive AVP antagonist that is selective for the V2 receptor
15). To further evaluate the role of the V2 receptor in heart
ailure and to determine the pharmacological potential of
his specific agent, we evaluated the effects of lixivaptan on
olute-free water excretion and on other parameters in 42
ew York Heart Association (NYHA) functional class II or
II heart failure patients.
ETHODS
his was a randomized, double-blind, placebo-controlled,
scending, single-dose safety, efficacy, and tolerability study
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V2 Receptor Antagonism in Heart Failure April 18, 2006:1615–21f lixivaptan in patients with chronic symptomatic heart
ailure requiring diuretic therapy. Subjects were enrolled at
wo centers: the University of Colorado Health Sciences
enter and the University of Iowa Hospitals and Clinics.
he investigational review boards and the General Clinic
esearch Center (GCRC) scientific advisory committees of
ach participating institution approved the study protocol,
nd all patients provided written informed consent.
ubjects. Adult men or women with NYHA functional
lass II or III systolic heart failure (left ventricular ejection
raction 35% documented within three months of study
nrollment), serum sodium concentration of 120 to 140
mol/l, and serum potassium concentration in the normal
ange were eligible for the study. Patients were excluded
rom study for a variety of medical reasons including a
ystolic blood pressure of 90 mm Hg, hypertrophic
bstructive or restrictive cardiomyopathy, significant valvu-
ar obstruction, sustained ventricular tachycardia, or ventric-
lar fibrillation within 30 days, recent myocardial infarction
r cardiac surgery, intrinsic renal or hepatic insufficiency,
nd the inability to withhold heart failure medications other
han digitalis for at least 48 h before study drug adminis-
ration until 48 h after study drug administration. Signifi-
ant renal impairment was defined as an estimated glomer-
lar filtration rate 40 ml/min using the Cockroft-Gault
ormula (16). Hepatic insufficiency was defined by serum
minotransferases, bilirubin, or alkaline phosphatase 3
imes the upper limit of normal.
tudy protocol. Patients were screened for eligibility
ithin seven days of study participation. Diuretics,
ngiotensin-converting enzyme inhibitors, other heart fail-
re medications (with the exception of digitalis), and
on-steroidal anti-inflammatory drugs were withdrawn at
east one day before admission to the GCRC. Patients were
dmitted to the study centers on day 2 (two days before
tudy drug administration), and a complete clinical evalua-
ion was performed. This included a physical examination
ith body weight, vital signs, temperature, respiratory rate,
nd orthostatic blood pressure and heart rate, 12-lead
lectrocardiogram, chest X-ray, and laboratory evaluation.
aseline biochemistry assessment included serum electro-
ytes, osmolality, creatinine, urea nitrogen, and liver func-
ion studies; a complete blood count and coagulation profile
ere also performed. Upon admission to the GCRC,
atients were placed on a standardized low-normal sodium/
Abbreviations and Acronyms
AQP-2  aquaporin-2
AVP  arginine vasopressin
CHF  chronic heart failure
CNS  central nervous system
ECF  extracellular fluid
GCRC  General Clinic Research Center
NYHA  New York Heart Associationotassium diet consisting of 100 to 120 mmol of sodium nd 50 to 60 mmol of potassium daily. The consumption of
ny alcohol or xanthine-containing products (e.g., coffee,
ea, chocolate) was prohibited throughout the study period.
On the day before study drug administration (day 1;
aseline or mock dose day), all patients received a single-
lind placebo, and this mock dose served as a baseline for
omparison with day 1 (study drug administration day). On
ay 1, patients received double-blinded study medication:
ne of six different doses of the selective V2 receptor
ntagonist lixivaptan or placebo by mouth. The doses of
ixivaptan were 10, 30, 75, 150, 250, and 400 mg. For each
ose group, five patients were randomized to active study
rug, and two patients were randomized to placebo. Ad-
inistration of the next higher dose level proceeded only
fter blinded safety data obtained from the preceding dose
roup had been evaluated by the study’s principal investi-
ator (W.T.A.) and the study sponsor.
On both study days (day 1 and day 1), serum electro-
ytes, osmolality, creatinine, and urea nitrogen were mea-
ured at 0, 1, 2, 4, 8, 12, and 24 h of the study period.
wenty-four hour regular urine collections (bladder cathe-
ers were not used, because of potential for infection, albeit
mall) for measurement of urine volume, electrolytes, cre-
tinine, and osmolality were also performed on both days.
rine was collected in timed increments of 0 to 2, 2 to 4, 4
o 6, 6 to 8, 8 to 12, and 12 to 24 h to examine the time
ourse of effect of the study medication. Neurohormones,
ncluding plasma renin activity, aldosterone, norepineph-
ine, endothelin-1, and atrial natriuretic peptide, were
easured at 0, 2, 4, 8, and 24 h. After patients had been
upine for at least 30 min, plasma AVP levels were assessed
t 0, 0.5, 1, 2, 4, 8, 12, and 24 h. Food and fluids, including
ater, were prohibited for 8 h before and 4 h after the mock
r study drug dose administration. However, if a patient
rinated 3 l during the 4-h post-dose period on day 1 or
f the investigator thought that patient safety would be
ompromised by a continued fast, the patients were allowed
ree access to water before the 4-h time point.
tatistical methods. Kruskal-Wallis tests were performed to
xamine the equivalence of dose groups on baseline character-
stics. After normalizing transformations were applied to adjust
or skewness, mixed model longitudinal data analysis was
erformed using SAS PROC MIXED (SAS Institute, Cary,
orth Carolina) to determine the effects of dose, time, and day
baseline [day 1] and placebo vs. active treatment) on urine
olume, urine flow, urine osmolality, solute-free water clear-
nce, serum osmolality, serum sodium, and plasma vasopressin
oncentration. For each dependent variable, the best fitting
odel was determined by the smallest value of Akaike’s
nformation criterion. The Tukey-Kramer multiple compari-
on adjustment for p values was applied to all longitudinal data
nalysis. Differences among dose groups between day 1
baseline) and day 1 (active treatment) at each time point were
urther delineated using analysis of variance. A p value of0.05 was considered significant.
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emographics and baseline characteristics of patients.
orty-two patients with congestive heart failure enrolled in
nd completed the study. Given the randomization scheme
f 5 active to 2 placebo subjects per dose group, a total of 12
atients were allocated to the placebo group. The baseline
emographic characteristics of these patients, by dose group,
re presented in Table 1. Although there were differences in
ace, gender, and age between the groups, the baseline control
rine data was comparable (not shown).
ffect on urine flow. Baseline (day 1) urine volume did
ot change significantly during 24 h of observation in
atients assigned to the six different doses groups; there was
owever a slight, although insignificant, increase during the
-to-8-h period, which corresponded to the postprandial
eriod. On day 1, significant dose-related increases in urine
olume were observed at lixivaptan doses greater than 10
g. This effect was particularly apparent at all doses greater
han 10 mg during the first 4 h (data not shown). During 24 h,
ncreases in urine volume ranged from 1.8 l with placebo to
.9 l after the 400-mg dose of lixivaptan (p  0.01).
Urine flow rate was increased for all doses groups (Fig. 1).
t hour 1, urine flow was significantly greater with doses of
5 mg (p  0.05), 250 mg (p  0.01), and 400 mg (p 
.01) as compared with placebo. Urine flow rate was
ignificantly greater at 2 h with doses of 30, 75, 150, 250,
nd 400 mg (all p  0.001) compared with the placebo. At
our 4, urine flow remained significantly higher with doses
f 250 mg (p 0.001) and 400 mg (p 0.001) as compared
ith placebo. Urine flow rate remained significantly higher
Table 1. Characteristics of the CHF Patients b
Characteristics
Placebo 10 mg
(n  12) (n  5)
Age (yrs)
Mean 55.8 58.8
SD 15 14.4
Range 30–81 39–76
Gender, n (%)
Female 4 (33) 1 (20)
Male 8 (67) 4 (80)
Ethnic origin, n (%)
White 11 (92) 2 (40)
Black 1 (8) 2 (40)
Hispanic 0 (0) 1 (20)
Asian 0 (0) 0 (0)
Height (inches), n
Mean 65.9 66.7
SD 4.7 2.5
Range 57–72 64–71
Weight (kg), n
Mean 83.9 81.6
SD 28.5 13.7
Range 52–161 63–100
NYHA functional class
II 6 2
III 6 3
CHF  chronic heart failure; NYHA  New York Heart Aith a dose of 400 mg (p  0.01) as compared with the 1lacebo until hour 8. Significant differences in urine flow
ate occurred at 2 h between baseline (day 1) and
reatment period (day 1) for 30 mg and higher doses (all p 
.001). At hour 4, urine flow rate remained significantly
igher with the 250-mg (p  0.001) and 400-mg (p 
.001) doses as compared with the baseline study day. Urine
ow rate was still significantly higher with the 400-mg dose
p  0.01) at 6 and 8 h as compared with the baseline.
ffect on urine osmolality. At baseline, urinary osmolality
as on average elevated consistent with the water-retaining
ature of these subjects. Significant reductions in urinary
smolality were achieved in all patients administered lix-
vaptan as compared with the placebo group. This decrease
nd its duration was dose-related (linear p  0.001 for dose
esponse). By hour 1, urine osmolality decreased signifi-
antly with doses of 30 mg (p  0.01), 150 mg (p  0.05),
50 mg (p 0.001), and 400 mg (p 0.01) compared with
lacebo. The minimal urine osmolality values were achieved
ithin the first 2 h after drug administration for all groups
0 mg and higher with the greatest response with a dose of
00 mg. At hour 4, urine osmolality remained significantly
ower with doses of 75, 150, 250, and 400 mg (all p 
.001) as compared with placebo. At 6 h, urine osmolality
emained significantly lower with a dose of 400 mg (p 
.01) as compared with placebo. Urine osmolality was
ignificantly lower with doses of 30 mg (p  0.001), 75 mg
p  0.01), 150 mg (p  0.001), 250 mg (p  0.01), and
00 mg (p  0.001) during the treatment period (day 1) as
ompared with day 1 at hour 2. Urine osmolality re-
ained significantly lower with doses of 75 mg (p  0.05),
ose Group
g 75 mg 150 mg 250 mg 400 mg
5) (n  5) (n  5) (n  5) (n  5)
6 51.6 52.4 53.6 51.8
8 4 6.5 7.9 13.9
7 46–56 42–59 46–64 33–68
— 2 (40) 1 (20) 2 (40)
0) 5 (100) 3 (60) 4 (80) 3 (60)
0) 2 (40) 0 (0) 5 (100) 4 (80)
3 (60) 4 (80) 0 (0) 1 (20)
0 (0) 0 (0) 0 (0) 0 (0)
0 (0) 1 (20) 0 (0) 0 (0)
9 69.3 66.1 63.8 67.2
6 3.1 3.2 7.6 4
3 67–74 60–68 52–70 62–71
2 78.4 85.7 81.4 95.7
2 11.8 6.9 11.5 19.2
10 62–95 77–96 70–101 67–121
2 2 4 1
3 3 1 4
tion; SD  standard deviation.y D
30 m
(n 
56.
7.
47–6
—
5 (10
5 (10
0 (0)
0 (0)
0 (0)
68.
3.
64–7
87.
19.
67–1
3
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V2 Receptor Antagonism in Heart Failure April 18, 2006:1615–21.001) at hour 4 and remained lower with doses of 150 mg
p  0.01), 250 mg (p  0.01), and 400 mg (p  0.001) at
our 6 as compared with baseline (day 1).
No significant differences were observed for urinary
odium, potassium, chloride, magnesium, or urea nitrogen
xcretion (data not shown).
ffect on solute-free water excretion. Lixivaptan dramat-
cally increased solute-free water excretion during the first
-h period after study drug administration as compared with
he placebo (Fig. 2). During the 0-to-2-h period, solute-free
ater excretion was significantly greater with doses of 30 mg
p 0.05), 75 mg (p 0.001), 150 mg (p 0.001), 250 mg
p  0.01), and 400 mg (p  0.001) compared with
lacebo. Solute-free water excretion was significantly greater
igure 1. Urine flow rates for the groups randomized to lixivaptan or pl
baseline). The bottom panel depicts results after administration of doub
ixivaptan as indicated. At 1 h, urine flow was significantly increased at the
oses 10 mg. See text for specific p values.uring the 2-to-4-h period with doses of 10 mg (p  0.05), t0 mg (p 0.05), and 75, 150, 250, 400 mg (all p 0.001)
ompared with the placebo. During the 4-to-6-h period,
olute-free water excretion remained significantly greater
ith doses of 250 mg (p  0.01) and 400 mg (p  0.01)
ompared with the placebo. Although solute-free water
xcretion remained positive for the 250- and 400-mg doses,
he effect did not reach significance at the 6-to-8-h period.
eak effects ranged from 3 ml/min after 30 mg to 5.7
l/min after 400 mg; this peak effect occurred within the
rst 2-h period after study drug administration. Compared
ith baseline (day 1), solute-free water excretion was
ignificantly greater with doses of 30 mg (p 0.001), 75 mg
p  0.01), 150 mg (p  0.001), 250 mg (p  0.01), and
00 mg (p  0.001) during the first 2-h period and during
. The top panel presents data after single-blind placebo administration
nd study medication, consisting of either placebo or one of six doses of
er doses of lixivaptan. At 2 h, urine flow was significantly increased at allacebo
le-bli
highhe 2-to-4-h period with doses of 10 mg (p  0.05), 30 mg
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April 18, 2006:1615–21 V2 Receptor Antagonism in Heart Failurep  0.05), 75 mg (p  0.05), 150 mg (p  0.001), 250 mg
p  0.05), and 400 mg (p  0.05) during the treatment
eriod (day 1).
ffect on serum osmolality, serum sodium, and serum
lectrolytes. At hour 2, serum osmolality was significantly
igher with doses of 150 mg (p  0.01) and 400 mg (p 
.05) compared with the placebo. Serum osmolality was also
ignificantly higher with a dose of 400 mg at hour 4 (p 
.01) and hour 8 (p  0.05) compared with the placebo. A
ignificantly higher serum osmolality occurred on the treat-
ent period (day 1) as compared with baseline (day 1) at
oses of 75 mg (p  0.05), 150 mg (p  0.05), and 250 mg
p  0.05) at hour 2. At hour 4, serum osmolality remained
igure 2. Effect of V2 antagonism on solute-free water excretion. The to
ottom panel depicts results after administration of double-blind study med
ixivaptan dramatically increased free water excretion within the first 2 hignificantly higher with doses of 75 mg (p 0.05), 250 mg ap  0.01), and 400 mg (p  0.05) compared with the
aseline (day 1).
At hour 2, serum sodium concentration was significantly
igher with doses of 150 mg (p  0.05) and 250 mg (p 
.05), and at hour 4 with doses of 150 mg (p  0.001) and
50 mg (p  0.05) compared with baseline (day 1). After
ctive study drug administration, no significant differences
ere seen in serum chloride, magnesium, blood urea nitro-
en, and potassium concentrations when compared with
lacebo or baseline (day 1) (data not shown).
ffect on plasma concentration of vasopressin and other
ormones. At time 0.5 h, plasma AVP concentrations
ere similar for all doses. By 2 h, a dose of 400 mg was
el presents data after single-blind placebo administration (baseline). The
n, consisting of either placebo or one of six doses of lixivaptan as indicated.
study drug administration. See text for specific p values.p pan
icatiossociated with an increase in AVP concentration as com-
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V2 Receptor Antagonism in Heart Failure April 18, 2006:1615–21ared with placebo (2.21 1.04 vs. 0.83 0.64 pg/ml, p
.05). Arginine vasopressin concentration increased signif-
cantly with doses of 150 mg (p  0.05), 250 mg (p 
.001), and 400 mg (p  0.001) as compared with placebo
t hour 4. Moreover, AVP concentrations were significantly
igher with doses of 250 mg and 400 mg from 2 to 8 h
ompared with baseline (day 1) (p  0.05). However, the
aximum AVP concentration after study drug administra-
ion did not exceed 3.5 pg/ml, on average, or 6.6 pg/ml in
ny individual patient. No significant differences occurred
or plasma renin, aldosterone, atrial natriuretic peptide,
ndothelin-1, and norepinephrine as compared with placebo
r baseline (day 1) (data not shown).
olerability and adverse effects. The study medication
as well tolerated in these heart failure patients. There were
o serious adverse events reported. Four events were con-
idered potentially serious (two possibly study drug related,
achyarrhythmia and bradyarrhythmia) but resolved with
ppropriate medical intervention. The most frequent ad-
erse events of any sort included diarrhea (three), headache
two), dizziness (three), orthostatic tachycardia (two), dry
outh (two), and flatulence (two). There were no consistent
ositive or negative trends in clinical chemistry, ECGs, or
ital signs.
ISCUSSION
his study represents the most extensive evaluation of the
enal and biochemical effects of an AVP antagonist in
ater-retaining heart failure patients. These findings dem-
nstrate a dose-related increase in urine volume, urine flow
ate, and solute-free water excretion, compatible with the
xpected aquaretic effect of a V2 receptor antagonist. At
igher doses, serum sodium concentration was increased
ithin the normal range. There was no increase in urinary
olute excretion or neurohormonal activation (with the
xception of plasma AVP) and no decrease in renal func-
ion, as measured by blood urea nitrogen and serum creat-
nine (data not shown). The increase in plasma AVP
ccurred only at the higher doses of study medication and
emained within the “physiologic” range seen in heart failure
atients. These findings suggest a role for AVP in the water
etention associated with heart failure and demonstrate the
otential utility of AVP antagonists for its treatment.
Our earlier preliminary report provided evidence that this
2 receptor antagonist was associated with a dose-
ependent decrease in the excretion of urinary AQP-2, the
VP-sensitive water channel expressed in collecting duct
ells within the kidney (17). This observation suggests the
echanism of action of the AVP antagonist, whereby
lockade of the renal V2 receptor results in decreased
rafficking of AQP-2 to the apical membrane and a reduc-
ion in the distal reabsorption of water.
There were several important controls in this randomized
rial including the day1 and placebo results. Because fluid
ntake was restricted for 4 h after V2 antagonist adminis- (ration, a rise in plasma AVP concentration and increase in
erum osmolality and sodium concentration were associated
ith the negative water balance. Whether a chronic increase
n plasma AVP concentration during V2 antagonist admin-
stration could eventually blunt the agent’s effect cannot be
etermined from the present results. However, in a study of
0 hyponatremic cirrhotic patients of one-week duration, no
vidence of tachyphylaxis was observed during chronic
ixivaptan administration (18). With the presence of a stable
ntagonist effect on the V2 receptor, the ultimate plasma
smolality and sodium concentration obviously will depend
n the balance between water intake and the solute-free
ater excretion.
While patients enrolled into this study showed water
etention rather than a low serum sodium concentration, the
esults support a role for V2 receptor antagonists in the
reatment of dilutional hyponatremia. These findings are
ompatible with the experience in a large number of heart
ailure patients using lixivaptan (19,20) and another V2
ntagonist (tolvaptan; OPC-41061) (21) that has shown a
ormalization of serum sodium in patients with hyponatre-
ia. This effect of V2 antagonism is of potential impor-
ance. First, there are central nervous system (CNS) effects
f hyponatremia including lethargy, difficulty in concentra-
ion, disorientation, seizures, and even coma depending on
he severity and rapidity of the decrease in plasma sodium
oncentration. In symptomatic heart failure patients, cere-
ral perfusion may already be impaired, and therefore the
NS consequences of hyponatremia may be exaggerated,
ven at levels of hyponatremia considered to be mild; this
ossibility however remains to be proven. Thus, V2 antag-
nist administration may be useful in treating symptomatic
yponatremia in the heart failure patient (22). Second,
re-treatment hyponatremia is also associated with in-
reased mortality in heart failure patients (2). It is not
nown, however, whether the hyponatremia is merely a marker
f severity of the cardiac dysfunction or whether is it also of
athogenetic significance. However, cardiac arrest is an impor-
ant cause of death in patients with heart failure, and in heart
ailure patients, hyponatremia may be associated with an
ncreased occurrence of arrhythmias (23). Finally, in vitro
esearch supports an effect of extracellular sodium concen-
ration on the vascular smooth muscle response to vasocon-
trictor agents. A decrease in extracellular sodium concen-
ration in cultured vascular smooth muscle cells has been
hown to increase cytosolic ionized calcium concentration
nd enhanced contractility in response to vasoconstrictor
gents (24). If these in vitro results are applicable in vivo,
hen hyponatremia potentially could increase cardiac after-
oad and myocardial irritability in patients with heart failure
ho are known to have increased plasma concentrations of
ngiotensin II and norepinephrine.
No neurohormonal changes were reported during the use
f lixivaptan. In contrast to an excretion of isotonic solute
ith diuretics that all comes from the extracellular fluidECF) volume, solute-free water excretion comes two-
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April 18, 2006:1615–21 V2 Receptor Antagonism in Heart Failurehirds from intracellular volume and only one-third from
CF potentially blunting any neurohormonal stimulation.
he small number of patients could have also contributed to
o detectable changes in neurohormones, except vasopres-
in, which is very sensitive to an increase (1% to 2%) in
lasma osmolality.
In summary, this study implicates AVP in the water
etention seen in heart failure and supports ongoing clinical
esearch evaluating the safety and efficacy of V2 receptor
ntagonists in heart failure patients. The potential use of
hese agents as aquaretic agents is supported by the present
bservations. The effect of such agents on heart failure
utcomes requires evaluation in large-scale morbidity and
ortality studies.
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